Table 2 Distribution of Growth in Culture and Use of Nephrotoxic Agents by Patients
From: Nephrotoxicity caused by colistin use in ICU: a single centre experience
Characteristics | Total (n = 148) | Non-AKI (n = 94) | AKI (n = 54) | p-value |
|---|---|---|---|---|
Growths | ||||
Blood | 15 (10.1) | 11 (11.7) | 4 (7.4) | 0.582 |
Urine | 7 (4.7) | 6 (6.4) | 1 (1.9) | 0.423 |
Wound | 4 (2.7) | 1 (1.1) | 3 (5.6) | 0.138 |
Causative organism, n (%) | Growth = 147 | Growth = 90 | Growth = 57 | |
Acinetobacter baumannii | 118 (80.3) | 74 (82.2) | 44 (77.2) | 0.593 |
Klebsiella pneumoniae | 19 (12.9) | 9 (10.0) | 10 (17.5) | 0.282 |
Pseudomonas aeruginosa | 10 (6.8) | 7 (7.8) | 3 (5.3) | 0.741 |
Nephrotoxic agent, n (%) | 68 (45.9) | 38 (40.4) | 30 (55.6) | 0.108 |
Concomitant vancomycin | 51 (34.5) | 26 (27.7) | 25 (46.3) | 0.034 |
Concomitant aminoglycoside | 19 (12.8) | 14 (14.9) | 5 (9.3) | 0.465 |
Concomitant NSAIDs | 1 (0.7) | 1 (1.1) | 0 (0) | 1.000 |
Concomitant amphotericin | 5 (3.4) | 3 (3.2) | 2 (3.7) | 1.000 |